lI VI VC) TREATMENT with antineoplastic drugs has been found to increase the antigenicity of mouse tumour cells (Melan et al., 1968; Mihich, 1969; Bonmassar et al., 1970; Nicolin et al., 1972 , Fuji et al., 1973 . These new antigenic specificities were not detected on parental cells, and were transmissible, as a genetic character, after the withdrawal of the drug (Nicolin et al., 1974) . The pharmacologically induced antigenic alteration of tumour cells may lead to their rejection on inoculation into syngeneic hosts. An understanding of the immune reactivity to drug-induced antigens might lead to new methodologies for the experimental immunotherapy of murine neoplasms, designed to eradicate cancer cells totally (Oettgen, 1977) . In a series of previous studies, drug-xenogenized tumour cells were found to elicite cellular rather than humoral immune responses (Testorelli et al., 1978; Fioretti et al., 1978) . Antibodies specific to drug-induced antigens have been detected by a number of assays, including binding of radioiodinated immunoglobulin of hyperimmunized syngeneic animals (Kitano et al., 1972) , a modified plaque assay (Fuji & Mihich, 1975) and direct, complement-dependent cytotoxicity (Nicolin et al., 1976a) . In these studies, the activity, though specific and reproducible, was generally not extensive. In the present study, the serum of mice challenged with L5178Y lymphoma cells antigenically altered by treatment with the anticancer drug 5(3,3-dimethyl triazeno) imidazole-4-carboxamide (DTIC) was used to determine the extent of antibody-dependent cellular cytotoxicity (ADCC) against the DTIC-altered tumour cells.
Animals and tumours.-Three-month-old inbred DBA/2Cr, BALB/c, C57BL/6J, C3H male mice, hybrid (BALB/cxDBA/2Cr) F1 male mice, hereafter called CD2F1, obtained from the Charles River Breeding Laboratories, Calco, Italy, and 12-15 week-old SpragueDawley male rats obtained from FarmitaliaCarlo Erba, Milan, Italy, were used in the experiments. L5178Y lymphoma (LY) chemically induced in DBA/2 mice (kindly supplied by Dr P. Alexander, Sutton, England) was maintained by weekly i.p. passages in compatible animals. The LY/ DTIC subline was obtained by daily in vivo treatment of the parental LY lymphoma with DTIC (100 mg/kg i.p.) for 5 transplant generations, as previously described (Nicolin et al., 1976b) , and maintained by in vivo passages in CD2F1 mice that had been immunosuppressed with cyclophosphamide (200 mg/kg i.p.) 24 h before tumour inoculation.
Drugs.-DTIC highest serum concentrations, as reported by other authors in different tumour systems, and a fall of activity at serum dilutions between 1/64 and 1/512 were seen. Lysis did not occur with LY target cells or unrelated target cells, nor were X-ray-inactivated LY cells able to elicit immune sera with ADCC activity (data reported here). Fig. 3 show that cell lysis was obtained when the ADCC assay was conducted in the presence of serum during the 4h inoculation. Although the pattern of lytic activity was similar to that obtained with precoating target cells before the incubation with effector cells (Fig. 2 ) the specific percentage of 51Cr release was significantly reduced.
The genetic background of the effector cells did not substantially alter the results of the ADCC assay. As shown in Fig. 4 , the pattern of the reaction was maintained, though the peak target-cell lysis was obtained at a lower dilution (1/32). The specificity was mediated by anti-LY/ DTIC antibodies, while unprimed cells from different species have been the Fc+ populations, antibody-dependent for cell lysis. Anti-LY serum did not show ADCC activity in the assay with allogeneic or xenogeneic lymphocytes (data not reported here). The kinetics of antibody production after challenge with LY/ DTIC cells is reported in Fig. 5 Fig. 6 shows the ADCC activity of serum from individual animals. Target cells coated with serum from CD2F1 mice challenged with 10 x 106 LY/DTIC cells i.p. showed differences in susceptibility to lysis by C57BL/6J lymphocytes. Despite the individual variability of the sera in mediating in vitro ADCC, the pattern of the activity was similar to that observed with pooled sera.
DISCUSSION
It is well established that target-cell destruction can be mediated through different immunological mechanisms (Cerottini & Brunner, 1977) . Specific cellular lysis of tumour cell is mainly performed by the classic T-cell immunity mechanism (Cerottini & Brunner, 1974) or the interaction of antibody with normal lymphoid cells, the latter being referred to as antibody-dependent cellular cytotoxicity (ADCC). The precise mechanism of ADCC is not understood, though it is known that the specificity of this imimunological reaction is determined by antibody bound to membrane-associated (Lamon et al., 1976; Shore et al., 1976a) and also against Durantez & Zighelboim, 1976) , histocompatibility (Yust et al., 1974;  A@~~~s s , Jeannet & Vassalli, 1976) or auto-antigens (Feldmann et al., 1976) . It would appear that any cell in which a virus is replicating has alterecl membrane properties which make that cell susceptible to destruction by this mechanism (Shore et al., 1976b no activity in the direct, complementdependent assay. Complement,-dependent humoral cytotoxicity could be detected (never above 20% specific 51Cr release) in the serum of animals only after multiple immunizations, and the activity was lost at serum dilutions effective in mediating ADCC. The activity mediated by the sera raised in syngeneic animals immunized with LY/DTIC cells was similar to that mediated by sera from animals bearing highly immunogenic tumours or challenged with histoincompatible cells (Blair et al., 1976) .
The current observations with DTICinduced antigens are consistent with previous studies with other transplantation antigens (de Landazuri et al., 1974 : Berger & Amos, 1977 in that the cytotoxic antibody synthesis was very low, in contrast with the marked synthesis of binding antibodies effective in the ADCC assay.
Although the molecular nature of these antigens has not yet been studied, our data may contribute to an understanding of their biological characteristics and to a definition of their immunological properties.
